老年霍奇金淋巴瘤患者的治疗
本文综述老年(60岁以上)霍奇金淋巴瘤的流行病学、疾病特征与治疗进展。老年患者约占全部霍奇金淋巴瘤的三分之一,但仅占当前临床试验受试者的5-10%。老年患者疾病更具侵袭性且预后特征不良,对根治性化疗耐受性显著降低,导致毒性过大及治疗延迟减量而治疗不足,存在显著未被满足的医疗需求。
要点
- 约三分之一的霍奇金淋巴瘤患者为老年人群,但当前临床试验中仅5-10%的受试者≥60岁。
- 老年霍奇金淋巴瘤以侵袭性疾病及B症状、晚期为主等不良预后特征为特点。
- 老年患者对根治性化疗耐受性显著降低,毒性过大及治疗延迟减量导致治疗不足。
核心结论
- 老年霍奇金淋巴瘤患者存在显著未被满足的医疗需求,需要毒性更低且有效的治疗,且该增长人群存在重要知识缺口。
研究设计与样本
- 本文为综述,总结老年霍奇金淋巴瘤患者的流行病学、疾病特征与治疗进展。
主要发现
- 过去数十年霍奇金淋巴瘤疗效显著改善,并随维布妥昔单抗及纳武利尤单抗、帕博利珠单抗等靶向治疗发展持续改善。
- 采用PET响应适应性策略可降低多数患者总体治疗强度,减少急性和晚期毒性。
- 上述进展主要限于年轻患者,60岁以上老年患者的进展远不明显。
- 约三分之一的霍奇金淋巴瘤患者属于老年人群,但当前霍奇金淋巴瘤临床试验中仅5-10%的受试者≥60岁。
- 老年霍奇金淋巴瘤以侵袭性疾病及B症状、晚期为主等不良预后特征为特点,且对根治性化疗耐受性显著降低,导致毒性过大及因治疗延迟和减量而治疗不足。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The outcome of patients with Hodgkin lymphoma (HL) has dramatically improved over the past decades and continues to improve with the development of novel targeted therapies, such as the immunoconjugate brentuximab vedotin and the checkpoint inhibitors nivolumab and pembrolizumab. Moreover, with the use of response-adapted strategies using positron-emission-tomography (PET), the overall intensity of treatment for most patients can be reduced, resulting in less acute and late toxicity. However, these advances are mainly restricted to younger patients, as advances in patients above the age of 60 years ('older' patients) have been much less pronounced. Furthermore, about one third of all HL patients are among the older population, but only 5-10% of the patients treated in current HL clinical trials are ≥60 years old. HL in older patients is characterized by aggressive disease and unfavourable prognostic features as B symptoms and predominance of advanced stages. In addition, tolerance to curative chemotherapy is drastically reduced in older patients resulting in excessive toxicity and insufficient treatment due to therapy delays and dose reductions. Therefore, there is a significant unmet medical need in older HL patients for less toxic and effective therapies, and an important gap of knowledge concerning this growing population of patients. Recent advances on epidemiology, characteristics and treatment of older HL patients will be summarized in this article.
引用
- Böll B, Görgen H. The treatment of older Hodgkin lymphoma patients. Br J Haematol. 2018. PMID: 30407626. doi:10.1111/bjh.15652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。